NMS-P937 (also know as NMS-P937; NMS1286937; NMS-P-937; NMS-P 937; Onvansertib) is an orally bioavailable, potent, selective, small-molecule Polo-like Kinase 1 (PLK1) inhibitor with potential antitumor activity.

GW843682X is a novel, potent, selective, ATP-competitive inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) with IC50s of 2.2 nM and 9.1 nM, respectively.

Volasertib (formerly also known as BI6727, BI-6727, BI 6727) is a novel and highly potent dihydropteridinone-based Plk1 (polo-like kinase 1) inhibitor with potential antineoplastic activity.

Rigosertib sodium (formerly known as ON-01910; ON01910; Estybon), the sodium salt of Rigosertib, is a novel, potent and non-ATP-competitive inhibitor of PLK1 with potential anticancer activity.

MLN0905 (MLN-0905; MLN 0905) is a novel, potent and selective small-molecule inhibitor of polo-like kinase-1 (PLK1) with potential antineoplastic activity.

HMN-176 is a novel and potent antitumor compound.

CFI 400437 HCl is a novel,potent and selective PLK4(polo-like kinase 4) inhibitor .

TAK-960 (TAK960) is a novel, investigational, orally bioavailable, and selective inhibitor of polo-like kinase 1 (PLK1) with anticancer activity. It inhibits PLK1 with an IC50 of 0.8 nM at 10 μM ATP; TAK-960 also shows inhibitory activities against PLK2and PLK3, with IC50s of 16.9 and 50.2 nM, respectively.PLK1 is a serine/threonine protein kinase involved in […]

Centrinone (LCR263; LCR-263; LCR 263) is a novel and potent inhibitor of polo-like kinase 4 (PLK4) with potential antineoplastic activity.